IFM Quattro and IFM Discovery (MA) are werefocused on the discovery and development of next-generation small molecule drugs that harness the power of the innate immune system to treat inflammatory diseases and cancer. Their programs were acquired by another company in 2022. They were members of the IFM family of companies, whose other members have included IFM Therapeutics (acquired by BMS in 2017 for its agonists of STING and NLRP3, for oncology), IFM Tre (acquired by Novartis in 2019 for its antagonists of NLRP3, for inflammation) and IFM Due (collaborating with Novartis since 2019 on its cGAS/STING antagonists, also for inflammation).